A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: Fetal risks and management of cerebral metastases

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 51, Issue 4, 2011, Pages 372-376

  Mandrawa, Christine L ^a   Stewart, Josephine ^b   Fabinyi, Gavin C ^c   Walker, Susan P ^a  

^a MONASH UNIVERSITY   (Australia)

^b Department of Medical Oncology ^*  (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

breast neoplasm; neoplasm metastasis; oligohydramnios; pregnancy; trastuzumab

Indexed keywords

CAPECITABINE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DECOMPRESSION SURGERY; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FETAL WELL BEING; FETUS RISK; GESTATIONAL AGE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOHYDRAMNIOS; OUTCOME ASSESSMENT; PARENT COUNSELING; PRIORITY JOURNAL; REMISSION; RISK BENEFIT ANALYSIS; STEREOTAXIC SURGERY; TUMOR VOLUME; UNPLANNED PREGNANCY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CRANIOTOMY; DECOMPRESSION, SURGICAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; OLIGOHYDRAMNIOS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; RADIOSURGERY; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 80051866523     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2011.01314.x     Document Type: Article

References (24)

1. Duchnowska R, Szczylik C,. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 2005; 31: 312-318. (Pubitemid 41001678)
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer; correlation of relapse and survival with amplication of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
4. Baselga J, Carbonell X, Castaneda N-J, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-2171. (Pubitemid 46218708)
5. Bader AA, Schlembach D, Tamussino KF, et al. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 2007; 8: 79-81. (Pubitemid 46043032)
6. Beale JMA, Tuohy J, McDowell SJ,. Herceptin (trastuzumab) therapy in a twin pregnancy associated with oligohydramnios. Am J Obstet Gynecol 2009; 201: 13-14.
7. Fanale M, Uyei A, Theriault R, et al. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 2005; 6: 354-356. (Pubitemid 41715698)
8. Pant S, Landon MB, Blumenfeld M, et al. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 2008; 26: 1567-1569.
9. Sekar R, Stone PR,. Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 2007; 110: 507-510. (Pubitemid 47417745)
10. Watson WJ,. Herceptin (Trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 2005; 105: 642-643. (Pubitemid 40271236)
11. Witzel ID, Mueller V, Harps E, et al. Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 2008; 19: 191-195.
12. Goodyer P, Cybulsky A, Goodyer C,. Expression of the epidermal growth factor in fetal kidney. Pediatr Nephrol 1993; 7: 612-615. (Pubitemid 23283869)
13. Weber-Schoendorfer C, Schaefer C,. Trastuzumb exposure during pregnancy. Reprod Toxicol 2008; 25: 390-391.
14. Azim HA Jr, Peccatori FA, Liptrott SJ, et al. Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol 2009; 6: 367-370.
15. Goodyer MJ, Ismail JRM, O'Reilly SP, et al. Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J 2009; 2: 9329.
16. Shrim A, Garcia-Bournissen F, Maxwell C, et al. Trastuzumab treatment for breast cancer during pregnancy. Can Fam Physician 2008; 54: 31-32. (Pubitemid 351198347)
17. Berveiller P, Mir O, Sauvanet E, et al. Ectopic pregnancy in a breast cancer patient receiving trastuzumab. Reprod Toxicol 2008; 25: 286-288.
18. Gori S, Rimondini S, De Angelia V, et al. Central nervous system metastases in HER-2-positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007; 12: 766-773. (Pubitemid 47328220)
19. Pestalozzi BC, Brignoli S,. Trastuzumab in CSF. J Clin Oncol 2000; 18: 2350-2351.
20. Leyland-Jones B,. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009; 27: 5278-5286.
21. Chen M, Coakley F, Kaimal A, Laros K,. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol 2008; 112: 333-340.
22. Kanal E, Barkovich S, Bell C, et al. ACR guidance document for safe MR practices. AJR Am J Roentgenol 2007; 188: 1447-1474. (Pubitemid 46866845)
23. Ng J, Kitchen N,. Neurosurgery and pregnancy. J Neurol Neurosurg Psychiatry 2008; 79: 745-752. (Pubitemid 351914718)
24. Waterson AM, Graham J,. Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 2006; 24: 321-322. (Pubitemid 46622061)